What´s new in science?

There is no every-day work in science! The multiplicity of methods required for addressing ever arising new key questions render science complex and fascinating at the same time. In our group, we are especially interested in biochemically understanding the pathways of programmed cell death (PCD) for a simple reason: We want to block those pathways and thereby prevent functional organ damage in a plethora of clinically relevant situations.

In 2008 it became evident what was anticipated long before: Necrosis, a pathophysiologic pattern that causes a broad range of acute and chronic disorders, is not like we thought ever since science emerged a "cellular accident" but a genetically determined, regulated, programmed event. Therefore, if we further unravell those pathways of programmed necrosis (PN), we, the cell death research community, will define new therapeutic targets. In fact, we allready identified some and likely there are many more to come! Take a look at the following pages to catch a first glance of the PCD-pathways that we think we understand until now.

The big challange certainly is to transfer these new results into every-day clinical routine. To block PCD in vivo, we employ the viral idea to transduce active recombinant proteins into the cell. We apply these fusion proteins in preclinical models of PCD with a special focus on acute kidney injury (AKI) and sepsis-models.